Amgen Inc. $AMGN Shares Bought by Cwm LLC

Key Points

• Cwm LLC boosted its Amgen stake by 4.2% in Q4 to 163,784 shares, worth about $53.61 million.
• Amgen topped Q4 estimates with EPS of $5.29 (vs. $4.76 expected) and revenue of $9.87 billion (vs. $9.46 billion), and set FY2026 EPS guidance of 21.600–23.000.
• The company declared a quarterly dividend of $2.52 (annualized $10.08, yield 2.9%, ex-dividend May 15), institutional investors own ~76.5% of the shares, and analysts' consensus rating is "Hold" with an average target of $356.24.

Cwm LLC lifted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 163,784 shares of the medical research company's stock after acquiring an additional 6,643 shares during the quarter. Cwm LLC's holdings in Amgen were worth $53,608,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in AMGN. Capital World Investors lifted its holdings in shares of Amgen by 11.5% in the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock worth $5,303,578,000 after purchasing an additional 1,935,876 shares during the last quarter. National Bank of Canada FI lifted its holdings in shares of Amgen by 237.7% in the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company's stock worth $346,076,000 after purchasing an additional 863,216 shares during the last quarter. Van ECK Associates Corp lifted its holdings in shares of Amgen by 71.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company's stock worth $383,254,000 after purchasing an additional 567,400 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Amgen by 91.6% in the 3rd quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company's stock worth $221,607,000 after purchasing an additional 375,463 shares during the last quarter. Finally, Danske Bank A S bought a new stake in shares of Amgen in the 3rd quarter worth approximately $101,076,000. Institutional investors own 76.50% of the company's stock.

Amgen Stock Down 0.8%

Shares of AMGN stock opened at $348.22 on Thursday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The stock has a market cap of $187.93 billion, a PE ratio of 24.47, a price-to-earnings-growth ratio of 3.30 and a beta of 0.47. The business's fifty day moving average is $363.86 and its 200-day moving average is $336.66. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to analysts' expectations of $9.46 billion. During the same period last year, the firm earned $5.31 EPS. The firm's revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen's dividend payout ratio (DPR) is 70.84%.

Analysts Set New Price Targets

AMGN has been the topic of several recent research reports. Weiss Ratings reissued a "buy (b)" rating on shares of Amgen in a report on Monday, December 29th. Piper Sandler lifted their target price on Amgen from $381.00 to $432.00 and gave the company an "overweight" rating in a research note on Wednesday, February 18th. Oppenheimer set a $400.00 target price on Amgen and gave the company an "outperform" rating in a research note on Thursday, January 29th. Jefferies Financial Group assumed coverage on Amgen in a research note on Tuesday, March 10th. They set a "hold" rating and a $350.00 target price on the stock. Finally, Barclays assumed coverage on Amgen in a research note on Friday, February 20th. They set an "equal weight" rating and a $350.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has an average rating of "Hold" and an average price target of $356.24.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.